Search research articles
Contact Us
Filters
Showing results (131-140 of 420) with videos related to
Page
of 42
Sort By:
Diagnostic Microbiology and Infectious Disease
|
October 2, 2012
Interim susceptibility testing for ceftaroline, a new MRSA-active cephalosporin: selecting potent surrogate β-lactam markers to predict ceftaroline activity against clinically indicated species
Ronald N Jones, Robert K Flamm, Helio S Sader, et al.
International Journal of Antimicrobial Agents
|
May 27, 2014
Ceftolozane/tazobactam activity tested against Gram-negative bacterial isolates from hospitalised patients with pneumonia in US and European medical centres (2012)
David J Farrell, Helio S Sader, Robert K Flamm, et al.
Antimicrobial Agents and Chemotherapy
|
March 6, 2025
Antimicrobial susceptibility of <i>Stenotrophomonas maltophilia</i> from United States medical centers (2019-2023)
Helio S Sader, Mariana Castanheira, S J Ryan Arends, et al.
Antimicrobial Agents and Chemotherapy
|
February 16, 2011
Antimicrobial activity of CXA-101, a novel cephalosporin tested in combination with tazobactam against Enterobacteriaceae, Pseudomonas aeruginosa, and Bacteroides fragilis strains having various resistance phenotypes
Helio S Sader, Paul R Rhomberg, David J Farrell, et al.
Pathology
|
July 17, 2010
Antimicrobial activity and spectrum of daptomycin: results from the surveillance program in Australia and New Zealand (2008)
Jan M Bell, John D Turnidge, Helio S Sader, et al.
Diagnostic Microbiology and Infectious Disease
|
December 21, 2002
Four-year evaluation of frequency of occurrence and antimicrobial susceptibility patterns of bacteria from bloodstream infections in Latin American medical centers
Helio S Sader, Ronald N Jones, Soraya Andrade-Baiocchi, et al.
Journal of Global Antimicrobial Resistance
|
November 23, 2016
Analysis of 5-year trends in daptomycin activity tested against Staphylococcus aureus and enterococci from European and US hospitals (2009-2013)
Helio S Sader, David J Farrell, Robert K Flamm, et al.
Diagnostic Microbiology and Infectious Disease
|
February 18, 2014
Antimicrobial activity of ceftaroline combined with avibactam tested against bacterial organisms isolated from acute bacterial skin and skin structure infections in United States medical centers (2010-2012)
Robert K Flamm, David J Farrell, Helio S Sader, et al.
International Journal of Antimicrobial Agents
|
March 18, 2014
Antimicrobial susceptibility of Gram-negative organisms isolated from patients hospitalised with pneumonia in US and European hospitals: results from the SENTRY Antimicrobial Surveillance Program, 2009-2012
Helio S Sader, David J Farrell, Robert K Flamm, et al.
The Journal of Antimicrobial Chemotherapy
|
February 25, 2014
Ceftazidime/avibactam activity tested against Gram-negative bacteria isolated from bloodstream, pneumonia, intra-abdominal and urinary tract infections in US medical centres (2012)
Robert K Flamm, David J Farrell, Helio S Sader, et al.
Page
of 42
Search research articles
Search
Showing results (131-140 of 420) with videos related to
Sort By:
Page
of 42
Diagnostic Microbiology and Infectious Disease
|
October 2, 2012
Interim susceptibility testing for ceftaroline, a new MRSA-active cephalosporin: selecting potent surrogate β-lactam markers to predict ceftaroline activity against clinically indicated species
Ronald N Jones, Robert K Flamm, Helio S Sader, et al.
International Journal of Antimicrobial Agents
|
May 27, 2014
Ceftolozane/tazobactam activity tested against Gram-negative bacterial isolates from hospitalised patients with pneumonia in US and European medical centres (2012)
David J Farrell, Helio S Sader, Robert K Flamm, et al.
Antimicrobial Agents and Chemotherapy
|
March 6, 2025
Antimicrobial susceptibility of <i>Stenotrophomonas maltophilia</i> from United States medical centers (2019-2023)
Helio S Sader, Mariana Castanheira, S J Ryan Arends, et al.
Antimicrobial Agents and Chemotherapy
|
February 16, 2011
Antimicrobial activity of CXA-101, a novel cephalosporin tested in combination with tazobactam against Enterobacteriaceae, Pseudomonas aeruginosa, and Bacteroides fragilis strains having various resistance phenotypes
Helio S Sader, Paul R Rhomberg, David J Farrell, et al.
Pathology
|
July 17, 2010
Antimicrobial activity and spectrum of daptomycin: results from the surveillance program in Australia and New Zealand (2008)
Jan M Bell, John D Turnidge, Helio S Sader, et al.
Diagnostic Microbiology and Infectious Disease
|
December 21, 2002
Four-year evaluation of frequency of occurrence and antimicrobial susceptibility patterns of bacteria from bloodstream infections in Latin American medical centers
Helio S Sader, Ronald N Jones, Soraya Andrade-Baiocchi, et al.
Journal of Global Antimicrobial Resistance
|
November 23, 2016
Analysis of 5-year trends in daptomycin activity tested against Staphylococcus aureus and enterococci from European and US hospitals (2009-2013)
Helio S Sader, David J Farrell, Robert K Flamm, et al.
Diagnostic Microbiology and Infectious Disease
|
February 18, 2014
Antimicrobial activity of ceftaroline combined with avibactam tested against bacterial organisms isolated from acute bacterial skin and skin structure infections in United States medical centers (2010-2012)
Robert K Flamm, David J Farrell, Helio S Sader, et al.
International Journal of Antimicrobial Agents
|
March 18, 2014
Antimicrobial susceptibility of Gram-negative organisms isolated from patients hospitalised with pneumonia in US and European hospitals: results from the SENTRY Antimicrobial Surveillance Program, 2009-2012
Helio S Sader, David J Farrell, Robert K Flamm, et al.
The Journal of Antimicrobial Chemotherapy
|
February 25, 2014
Ceftazidime/avibactam activity tested against Gram-negative bacteria isolated from bloodstream, pneumonia, intra-abdominal and urinary tract infections in US medical centres (2012)
Robert K Flamm, David J Farrell, Helio S Sader, et al.
Page
of 42